CLYM
NASDAQ · Biotechnology
Climb Bio Inc
$8.99
+0.12 (+1.35%)
Open$9.19
Previous Close$8.87
Day High$9.29
Day Low$8.84
52W High$18.33
52W Low$1.64
Volume—
Avg Volume1.46M
Market Cap591.02M
P/E Ratio—
EPS$-0.82
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
+190.4% upside
Current
$8.99
$8.99
Target
$26.11
$26.11
$17.52
$26.11 avg
$31.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 93.03M | 87.17M | 93.25M |
| Net Income | -25,402,018 | -21,372,578 | -19,024,947 |
| Profit Margin | -27.3% | -24.5% | -20.4% |
| EBITDA | -33,224,495 | -30,585,289 | -30,503,356 |
| Free Cash Flow | -14,578,727 | -14,999,377 | -17,296,703 |
| Rev Growth | -8.3% | +13.0% | +19.4% |
| Debt/Equity | 0.78 | 0.63 | 0.86 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |